Actively Recruiting
Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)
Led by Case Comprehensive Cancer Center · Updated on 2026-03-03
15
Participants Needed
1
Research Sites
48 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is for participants whose cancer is oligometastatic, meaning it has spread to up to five spots in their body and their doctor recommends that they have stereotactic body radiation therapy (SBRT) to treat these cancer sites. SBRT is a type of radiation therapy that may help people with oligometastatic disease live longer without cancer progression. SBRT is usually given in addition to other cancer treatments, like chemotherapy, immunotherapy, or hormone therapy. Preparing for SBRT can take up to a week or longer. This can make it harder for participants to receive SBRT and coordinate care. This can also mean a longer time until symptoms from cancer sites improve. Doctors would like to treat oligometastatic cancers more quickly by reducing the time it takes to plan for the SBRT. The typical workflow for SBRT includes doctors doing a simulation which requires a CT (Computerized Tomography) scan. The CT scan is used to create a treatment plan. It can take time to schedule this CT scan and then it normally takes another 5-10 days to create a treatment plan. A way to reduce the planning time for SBRT is to use the CT scan (or other radiology scan types, like magnetic resonance imaging \[MRI\] or positron emission tomography \[PET\]) that participants had when their cancer was diagnosed to plan their SBRT. This eliminates the scheduling of an additional CT scan and the 5-10 day planning time. This is called CTsim-free (CT simulation-free) treatment planning. CT-sim-free radiation therapy planning has been shown to be effective in treating cancers that are causing pain in people with more advanced or widespread cancers. This study is being done to find out if it is safe and effective to use CTsim-free planning for SBRT to treat oligometastases.
CONDITIONS
Official Title
Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have confirmed oligometastatic cancer with up to 5 active disease sites at enrollment
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) Performance status of 2 or less
- Estimated life expectancy of at least 3 months
- Considered a candidate for SBRT by the treating physician
- Prior chemotherapy or biological treatment allowed if stopped at least 1 week before and resumed no sooner than 1 week after radiation, except endocrine therapies which can continue
- Ability and willingness to sign written informed consent
- Have a diagnostic CT, MRI, or PET/CT scan of the treatment site(s) done within 30 days before consent
You will not qualify if you...
- Prior radiotherapy to any site overlapping with the planned treatment area
- Isolated vertebral metastases except for sacral spine; cervical, thoracic, and lumbar spine sites are not allowed
- Pregnant or breastfeeding women
- Women of childbearing potential must have a negative pregnancy test within 14 days of study entry or documented exception by physician or investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
Research Team
L
Lauren Henke, MD, MSCI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here